Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing 维亚生物科技进入CDMO业务，营收激增
Two key acquisitions last fall helped fuel five-fold rise in first-half revenue, as company swung back into profitability 去年秋天的两项重要收购帮助推动了维亚上半年收入的五倍增长，公司重新进入盈利状态。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.